文献速递关节外科

HINTEGRA假体全踝关节置换术151例的长期临床结局与假体生存率:至少10年随访

Long-Term Clinical Outcomes and Implant Survivorship of 151 Total Ankle Arthroplasties Using the HINTEGRA Prosthesis: A Minimum 10-Year Follow-up.
PubMed 文献 · J Bone Joint Surg Am · 2022-06-20

本研究在单一非研发中心分析HINTEGRA假体全踝关节置换术的长期结局,纳入151例至少随访10年的踝关节。所有临床评分和踝关节活动度从术前至术后2年、4至6年及≥10年显著改善(p < 0.001),43踝(28.5%)需翻修,假体总体生存率为93.5%。

要点

  • HINTEGRA假体全踝关节置换术后临床评分和活动度改善维持至少10年。
  • 43踝(28.5%)需翻修,最常见原因为假体周围骨溶解(32踝,21.2%)。
  • Kaplan-Meier分析显示平均随访11.3年时假体总体生存率为93.5%。

核心结论

  • 使用HINTEGRA假体进行全踝关节置换术,配合仔细的随访观察和适当的辅助手术,治疗终末期踝关节炎产生了满意的临床结果,在≥10年随访时得以维持,假体生存率为93.5%。

研究设计与样本

  • 本研究在单一非研发中心分析了使用HINTEGRA假体的活动衬垫全踝关节置换术的长期结局。
  • 共对194例患者的213踝进行了初次全踝关节置换术,纳入其中136例患者的151个连续踝关节(71%),这些踝关节在初次全踝关节置换术后至少随访10年。
  • 临床结果采用视觉模拟量表(VAS)疼痛评分、美国足踝外科协会(AOFAS)踝-后足量表评分、踝关节炎量表(AOS)疼痛和功能障碍子评分以及踝关节活动度进行评估。
  • 同时评估了假体生存率、再手术和风险因素。

主要发现

  • 平均随访时间为135.5个月(范围120.0至204.0个月)。
  • 所有临床评分和踝关节活动度从术前至术后2年、4至6年及≥10年显著改善(p < 0.001)。
  • 共有43踝(28.5%)需要翻修手术,最常见原因为假体周围骨溶解(32踝,21.2%)。
  • 在平均随访11.3年时,Kaplan-Meier生存分析显示假体总体生存率为93.5%。

局限性

  • 证据等级为预后Level IV。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Few studies have investigated long-term clinical outcomes of a mobile-bearing total ankle arthroplasty (TAA) system. This study analyzed long-term outcomes of TAA using the HINTEGRA prosthesis at a single, non-developer center. METHODS: Primary TAAs were performed on 213 ankles in 194 patients, and 151 consecutive ankles [71%] in 136 patients with a minimum follow-up of 10 years after the primary TAA were included in this study. Clinical results were assessed using a visual analog scale (VAS) pain score, the American Orthopaedic Foot & Ankle Society (AOFAS) Ankle-Hindfoot Scale score, the Ankle Osteoarthritis Scale (AOS) pain and disability subscores, and ankle range of motion. Prosthesis survivorship, reoperations, and risk factors were also evaluated. RESULTS: The mean follow-up was 135.5 months (range, 120.0 to 204.0 months). All clinical scores and ankle range of motion improved significantly from preoperatively to 2 years, 4 to 6 years, and ≥10 years after TAA (p < 0.001). A total of 43 ankles (28.5%) required revision procedures, with the most common reason being periprosthetic osteolysis (32 ankles [21.2%]). The overall implant survivorship was 93.5% in Kaplan-Meier survival analysis at the mean follow-up of 11.3 years after the TAA. CONCLUSIONS: TAA using the HINTEGRA prosthesis with careful follow-up observation and appropriate adjunct procedures for the treatment of end-stage ankle arthritis produced satisfactory clinical results, which were maintained at a follow-up of ≥10 years, and resulted in 93.5% of implant survivorship. LEVEL OF EVIDENCE: Prognostic Level IV . See Instructions for Authors for a complete description of levels of evidence.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Yoon YK, Park KH, Park JH, et al. Long-Term Clinical Outcomes and Implant Survivorship of 151 Total Ankle Arthroplasties Using the HINTEGRA Prosthesis: A Minimum 10-Year Follow-up. J Bone Joint Surg Am. 2022. PMID: 35726878. doi:10.2106/JBJS.22.00060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。